Navigation Links
MicroRNA that blocks bone destruction could offer new therapeutic target for osteoporosis
Date:6/25/2014

DALLAS June 25, 2014 UTSouthwestern cancer researchers have identified a promising molecule that blocks bone destruction and, therefore, could provide a potential therapeutic target for osteoporosis and bone metastases of cancer.

The molecule, miR-34a, belongs to a family of small molecules called microRNAs (miRNAs) that serve as brakes to help regulate how much of a protein is made, which in turn, determines how cells respond.

UTSouthwestern researchers found that mice with higher than normal levels of miR-34a had increased bone mass and reduced bone breakdown. This outcome is achieved because miR-34a blocks the development of bone-destroying cells called osteoclasts, which make the bone less dense and prone to fracture.

"This new finding may lead to the development of miR-34a mimics as a new and better treatment for osteoporosis and cancers that metastasize to the bone," said senior author Dr. Yihong Wan, Assistant Professor of Pharmacology and member of the UTSouthwestern Harold C. Simmons Cancer Center.

Her team found that injecting nanoparticles containing an artificial version, or mimic, of miR-34a into a mouse with post-menopausal osteoporosis decreased bone loss. "Interestingly, the mouse miR-34a is identical to that in humans, which means that our findings may apply to humans as well," said Dr. Wan, Virginia Murchison Linthicum Scholar in Medical Research at UTSouthwestern.

The study is published online in the journal Nature.

High levels of bone destruction and reduced bone density caused by excessive osteoclasts are characteristic of osteoporosis, a common bone disease in which bones become fragile and susceptible to fracture. This condition disproportionately affects seniors and women, and leads to more than 1.5 million fractures annually.

miR-34a could have an additional therapeutic application, offering protection from bone metastases in a variety of cancers, Dr. Wan noted. Bone metastases happen when cancer cells travel from the primary tumor site to the bone, establishing a new cancer location. Researchers saw that injecting the miR-34a mimic in mice could prevent the metastasis of breast and skin cancer cells specifically to bone, mainly by disarming the metastatic niche in bone.

Co-author Dr. Joshua Mendell, Professor of Molecular Biology at UTSouthwestern and member of the UTSouthwestern Harold C. Simmons Cancer Center, noted that his laboratory previously showed that miR-34a can directly suppress the growth of cancer cells.

"We were very excited to see, through this collaborative work with Dr. Wan's group, that miR-34a can also suppress bone metastasis. Thus, miR-34a-based therapy could provide multiple benefits for cancer patients," said Dr. Mendell, CPRIT Scholar in Cancer Research. CPRIT is the Cancer Prevention and Research Institute of Texas, which provides voter-approved state funds for groundbreaking cancer research and prevention programs and services in Texas.


'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Why inflammation leads to a leaky blood-brain barrier: MicroRNA-155
2. Wound-healing role for microRNAs in colon offer new insight to inflammatory bowel diseases
3. MicroRNA that could be used to suppress prostate cancer progression found
4. MicroRNA could be key target for bowel cancer treatment
5. Fruit fly microRNA research at Rutgers-Camden offers clues to aging process
6. Viral microRNAs responsible for causing AIDS-related cancer, new USC study shows
7. Wayne State to study role of microRNAs in prostate cancer racial disparities
8. MicroRNA-31 might predict lung-cancer spread
9. Versatile microRNAs choke off cancer blood supply, suppress metastasis
10. Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
11. New papers identify a microRNA that drives both cancer onset and metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MicroRNA that blocks bone destruction could offer new therapeutic target for osteoporosis
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced ... Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR ... specializes in long-term care, Brooke Grove now has the capability to achieve its ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular SearchLight Spectra ... modeling resource for fluorescence microscopists and optical system designers, enabling The Right Solution, ... spanning the globe, SearchLight has become a tremendously popular tool for the fluorescence ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Healthcare companies ... But they will rapidly reject an outdated healthcare executive resume. , “If you’re a ... at your executive resume and wondering if it’s as ready as you are for ...
(Date:4/27/2017)... Reston, VA (PRWEB) , ... April 27, 2017 ... ... mobile application containerization, today announced an exhibitor sponsorship at MobileIron Live! 2017 ... leaders, and new technologies for an immersive, educational approach to helping organizations maximize ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is excited to announce ... present at the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego ... Canales will lend their expertise to the Premier Global Hot Topics session, speaking on ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: